Emcure Pharmaceuticals Ltd.
Price
Daily candles · NSEWhat the numbers say
- Good return on equity: 3-year ROE 19.6%.
- Comfortable leverage: debt-to-equity of 0.24.
- Sales compounded at 15.4% over 3 years.
- Weak cash conversion (CFO/OP 0.61).
- Trades above its industry P/E (36.5 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Emcure Pharmaceuticals gets EIR from USFDA for Sanand facility
The USFDA conducted this inspection from May 06, 2026 to May 15, 2026
- Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH
The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease
- Emcure Pharmaceuticals to acquire remaining 12.05% stake in Gennova
The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 9,204 | 7,896 | 6,658 | 5,986 | 5,855 |
| Other income | 131 | 73 | 57 | 46 | 63 |
| Total Income | 9,335 | 7,969 | 6,715 | 6,032 | 5,919 |
| Expenditure | 7,458 | 6,427 | 5,429 | 4,805 | 4,525 |
| Operating Profit | 1,877 | 1,542 | 1,287 | 1,227 | 1,393 |
| Interest | 144 | 176 | 237 | 214 | 176 |
| Depreciation | 415 | 384 | 312 | 260 | 245 |
| Profit before tax | 1,287 | 971 | 727 | 747 | 973 |
| Tax | 346 | 264 | 200 | 185 | 270 |
| Net Profit | 941 | 707 | 528 | 562 | 703 |
| EPS (₹) | 48.77 | 36.43 | 27.54 | 29.42 | 36.62 |
| Net margin % | 10.2 | 9.0 | 7.9 | 9.4 | 12.0 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 190 | 189 | 181 | 181 | 181 |
| Reserves | 4,748 | 4,245 | 2,757 | 2,305 | 1,791 |
| Net worth | 4,938 | 4,434 | 2,938 | 2,486 | 1,972 |
| Total sources | 5,602 | 5,444 | 4,458 | 3,614 | 3,056 |
| Net block | 3,319 | 3,197 | 3,125 | 2,147 | 2,044 |
| Capital work in progress | 273 | 177 | 159 | 411 | 320 |
| Investments | 269 | 268 | 465 | 179 | 159 |
| Inventory | 2,398 | 1,932 | 1,525 | 1,383 | 1,449 |
| Debtors | 2,563 | 2,002 | 1,859 | 1,648 | 1,309 |
| Cash & bank | 148 | 165 | 232 | 458 | 313 |
| Book value (₹) | 260.46 | 234.02 | 162.17 | 137.48 | 109.02 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 944 | 852 | 1,097 | 747 | 768 |
| From investing | -1,193 | -94 | -713 | -468 | -789 |
| From financing | 343 | -814 | -164 | -145 | -152 |
| Net change in cash | 94 | -56 | 221 | 134 | -172 |
| Free cash flow | -250 | 758 | 385 | 279 | -21 |
| Closing cash | 98 | -14 | 44 | -175 | -308 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 25.3 | 22.5 | 19.9 | 22.0 | 26.6 |
| ROE % | 20.1 | 19.2 | 19.5 | 25.2 | 33.2 |
| PAT margin % | 10.0 | 8.8 | 7.8 | 9.2 | 11.7 |
| EBIT margin % | 15.2 | 14.3 | 14.2 | 15.8 | 19.2 |
| Debt / equity | 0.24 | 0.17 | 0.71 | 0.88 | 1.05 |
| Current ratio | 1.43 | 1.71 | 1.33 | 1.27 | 1.15 |
| Interest cover | 9.96 | 6.53 | 4.07 | 4.50 | 6.53 |
| Sales growth % | 16.6 | 18.6 | 11.2 | 2.2 | -3.3 |
| Dividend per share (₹) | 3.60 | 3.00 | 3.00 | 2.00 | 3.00 |
| Payout % | 7.4 | 8.3 | 10.9 | 6.8 | 8.2 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Emcure Pharmaceuticals Ltd. (EMCURE) last traded at ₹1,782.60 on the NSE, up +1.57% on the session. Prices on this page are indicative and for information only.
Emcure Pharmaceuticals Ltd. has traded between ₹1,306.50 and ₹2,100.70 over the last 52 weeks on the NSE.
Emcure Pharmaceuticals Ltd. has a market capitalisation of about ₹33,796 crore.
Emcure Pharmaceuticals Ltd. trades at a P/E of 36.5, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for EMCURE from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Emcure Pharmaceuticals Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in